Laseroptek Co. Ltd., a developer and manufacturer of laser devices for aesthetic and medical dermatology, has announced the launch of its Pallas solid-state 311-nm UVB laser in the United States. The Pallas laser is FDA-cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma.
Pallas is the fifth Laseroptek laser device to receive FDA clearance in the U.S. for dermatological treatments and brings to the U.S. market the world's first solid-state UVB laser delivering efficacious and safe treatment for a variety of skin conditions that collectively affect close to a billion people worldwide.
Read more at PR Newswire >>